Clinical Trials
6 trialsNCT01141309 2025-07-22
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT00936858 2021-10-22
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03139747 2021-10-15
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Thomas Jefferson University
Phase 2 Suspended
NCT01270321 2021-02-17
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
Phase 2 Completed
NCT01164176 2014-12-02
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Phase 2 Completed
NCT01118065 2013-08-12
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown